Basiliximab can be administered safely and effectively in a single dose on day 1 postrenal transplantation in patients receiving triple therapy with azathioprine

Transplant Proc. 2001 Nov-Dec;33(7-8):3205-6. doi: 10.1016/s0041-1345(01)02364-8.

Authors

I Matl¹, P Bachleda, R Michalsky, P Navratil, M Lao, V Treska, H Prestele, M Matthisson, A Korn

Affiliation

¹ Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

PMID: 11750375
DOI: 10.1016/s0041-1345(01)02364-8

No abstract available

Publication types

Clinical Trial
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Azathioprine / therapeutic use*
Basiliximab
Brazil
Drug Therapy, Combination
Female
Graft Rejection / epidemiology
Graft Rejection / pathology
Graft Rejection / prevention & control
Histocompatibility Testing
Humans
Immunosuppression Therapy / standards
Infections / epidemiology
Kidney Transplantation / immunology*
Kidney Transplantation / pathology
Male
Middle Aged
Postoperative Complications / epidemiology
Recombinant Fusion Proteins*
Safety
Time Factors

Substances

Antibodies, Monoclonal
Recombinant Fusion Proteins
Basiliximab
Azathioprine